Share This Page
Deserpidine; methyclothiazide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for deserpidine; methyclothiazide and what is the scope of freedom to operate?
Deserpidine; methyclothiazide
is the generic ingredient in three branded drugs marketed by Abbott and Watson Labs, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Summary for deserpidine; methyclothiazide
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 2 |
| NDAs: | 3 |
| DailyMed Link: | deserpidine; methyclothiazide at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for deserpidine; methyclothiazide
US Patents and Regulatory Information for deserpidine; methyclothiazide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott | ENDURONYL FORTE | deserpidine; methyclothiazide | TABLET;ORAL | 012775-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | METHYCLOTHIAZIDE AND DESERPIDINE | deserpidine; methyclothiazide | TABLET;ORAL | 088452-001 | Aug 10, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Watson Labs | METHYCLOTHIAZIDE AND DESERPIDINE | deserpidine; methyclothiazide | TABLET;ORAL | 088486-001 | Aug 10, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abbott | ENDURONYL | deserpidine; methyclothiazide | TABLET;ORAL | 012775-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Deserpidine and Methyclothiazide Market Dynamics, Patent Status, and Financial Trajectory
Deserpidine/methyclothiazide is a legacy antihypertensive combination with no meaningful branded-market growth, limited commercial visibility, and an effectively expired intellectual-property position. The product combines deserpidine, a rauwolfia alkaloid that reduces sympathetic nervous-system activity, with methyclothiazide, a thiazide diuretic. Its clinical role has been displaced by newer thiazide-based regimens, renin-angiotensin system inhibitors, calcium-channel blockers, and fixed-dose combinations with stronger guideline support.
No reliable public source reports current product-level revenue for deserpidine/methyclothiazide. The commercial trajectory is best characterized as historical decline followed by residual, low-volume availability rather than an active growth market.
What is deserpidine/methyclothiazide and how does it work?
Deserpidine/methyclothiazide is an oral antihypertensive combination.
| Component | Pharmacologic role | Commercial implication |
|---|---|---|
| Deserpidine | Depletes catecholamines from sympathetic nerve endings and lowers vascular tone | Older mechanism with substantial tolerability and safety limitations |
| Methyclothiazide | Inhibits sodium reabsorption in the distal convoluted tubule | Established diuretic class, but less commonly selected than hydrochlorothiazide, chlorthalidone, or indapamide |
| Combination | Reduces blood pressure through complementary mechanisms | Fixed-dose convenience did not offset clinical displacement |
Deserpidine is associated with adverse effects characteristic of older sympatholytic agents, including nasal congestion, sedation, gastrointestinal effects, orthostatic symptoms, and depressive reactions. Methyclothiazide can cause hypokalemia, hyponatremia, hyperuricemia, glucose intolerance, and other thiazide-related effects. The combination therefore competes against better-established and more flexible antihypertensive options.
When did deserpidine/methyclothiazide enter the market?
The combination belongs to the first generation of fixed-dose antihypertensive products introduced during the mid-20th-century expansion of pharmacologic hypertension treatment. It has been marketed under the brand name Diupres and through generic or legacy-label channels.
The product predates the modern Hatch-Waxman patent framework and the current FDA exclusivity system. Its original commercial protection was based primarily on historical formulation and regulatory positioning rather than a modern patent estate covering a novel molecular entity.
Key historical timeline
| Period | Market event |
|---|---|
| 1950s-1960s | Reserpine-related and other rauwolfia-derived antihypertensive products enter clinical use |
| 1960s | Deserpidine/methyclothiazide combination products are marketed for hypertension |
| 1970s-1980s | Thiazide monotherapy and newer antihypertensive classes expand |
| 1990s | ACE inhibitors, calcium-channel blockers, beta blockers, and angiotensin-receptor blockers reduce use of rauwolfia combinations |
| 2000s | Product becomes a legacy antihypertensive with limited commercial differentiation |
| Current market | No credible evidence of meaningful branded growth or active innovation investment |
The FDA’s historical approval records and labeling databases identify the ingredients and product labeling, but they do not provide a current, standalone revenue series for the combination. (U.S. Food and Drug Administration, n.d.-a; National Library of Medicine, n.d.)
What patents protect deserpidine/methyclothiazide?
No active composition-of-matter patent is expected to protect deserpidine, methyclothiazide, or their combination. Both active ingredients were developed and marketed decades ago, placing any original patent protection far beyond the normal 20-year patent term established under modern U.S. patent law.
Patent-estate assessment
| IP category | Current assessment |
|---|---|
| Deserpidine composition patent | Expired or otherwise commercially irrelevant |
| Methyclothiazide composition patent | Expired or otherwise commercially irrelevant |
| Fixed-dose combination patent | Any original protection is expired |
| New formulation patents | No material active estate publicly associated with the legacy combination |
| Method-of-use patents | No significant current exclusivity identified |
| Manufacturing patents | No known barrier that would prevent conventional generic manufacture |
| Regulatory exclusivity | No current meaningful exclusivity expected |
| Trademark | Historical brand rights may exist but have limited economic value |
The commercial freedom-to-operate risk is therefore low for conventional tablets containing the two established active ingredients. Potential issues would relate to product-specific labeling, manufacturing controls, tablet design, or jurisdiction-specific registrations rather than core pharmaceutical patents.
What is the Orange Book status of deserpidine/methyclothiazide?
The product does not have the commercial profile of an actively protected reference product in the FDA Orange Book. The Orange Book is designed primarily to identify approved drug products, therapeutic-equivalence evaluations, patents submitted for listed products, and regulatory exclusivities. A legacy product may have historical approval records without having current patent or exclusivity protection.
A practical Orange Book assessment is:
- No active exclusivity period drives the U.S. market.
- No meaningful patent cliff remains.
- Any generic competition is not waiting for a near-term patent expiration.
- The principal barrier is commercial demand, not intellectual property.
FDA Orange Book listings and Drugs@FDA records should be distinguished from the existence of historical labeling. A product can have archived or legacy regulatory documentation without supporting a viable branded market. (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b)
When does deserpidine/methyclothiazide lose exclusivity?
The product’s core exclusivity expired many years ago. There is no commercially relevant future loss-of-exclusivity date comparable to products protected by modern composition patents, pediatric exclusivity, orphan exclusivity, or data exclusivity.
Exclusivity profile
| Protection type | Status |
|---|---|
| New chemical entity exclusivity | Expired |
| Composition-of-matter patent | Expired |
| Combination patent | Expired or immaterial |
| Pediatric exclusivity | Not commercially relevant |
| Orphan exclusivity | Not applicable |
| Biosimilar exclusivity | Not applicable |
| Current FDA marketing exclusivity | None of material commercial significance |
Because deserpidine/methyclothiazide is a small-molecule combination, biosimilar provisions do not apply. Generic approval, where available, would proceed through an abbreviated new drug application or another applicable small-molecule pathway rather than the biosimilar pathway.
Are there Paragraph IV challenges for deserpidine/methyclothiazide?
A commercially significant Paragraph IV campaign is unlikely. Paragraph IV litigation is generally used when a generic applicant challenges an unexpired patent listed for an approved reference drug. Deserpidine/methyclothiazide has no apparent active patent barrier that would justify a major current challenge.
No high-value, current Paragraph IV litigation involving this combination is a recognized driver of market access, valuation, or launch timing. Any historic generic filings would have had limited strategic value because the underlying product has low demand and limited pricing power.
What formulation patents protect the product?
No material current formulation patent estate is associated with the conventional deserpidine/methyclothiazide tablet.
The product’s formulation is technically straightforward:
- Oral tablet dosage form
- Fixed quantities of two established active ingredients
- Conventional excipients and compression processes
- No biologic manufacturing platform
- No depot injection, transdermal system, inhalation device, or complex delivery technology
A competitor could potentially design around a specific inactive-ingredient profile, tablet geometry, or manufacturing process without affecting access to the active ingredients. Those technical variables have little commercial importance unless a manufacturer is pursuing a narrow hospital, government, or specialty-distribution contract.
How strong is the patent estate for deserpidine/methyclothiazide?
The patent estate is weak from a business-development and litigation perspective.
| Patent-strength factor | Assessment |
|---|---|
| Remaining patent life | None of material value |
| Claim breadth | Legacy combination claims, if any, are no longer commercially blocking |
| Design-around difficulty | Low |
| Generic substitution risk | High where supply is available |
| Litigation leverage | Low |
| Licensing value | Minimal |
| Manufacturing defensibility | Low to moderate, based on quality and supply execution rather than IP |
The product may still have regulatory or operational barriers. A manufacturer must maintain compliant sourcing, validated production, stability data, pharmacovigilance, and reliable distribution. Those are execution requirements, not durable exclusivity mechanisms.
What is the competitive landscape for deserpidine/methyclothiazide?
The combination competes against therapies with stronger clinical adoption and broader formulary presence.
Main competitive classes
| Competitive class | Examples | Competitive advantage |
|---|---|---|
| Thiazide and thiazide-like diuretics | Hydrochlorothiazide, chlorthalidone, indapamide | Familiarity and guideline integration |
| ACE inhibitors | Lisinopril, enalapril | Strong evidence base and broad use |
| ARBs | Losartan, valsartan, irbesartan | Tolerability and fixed-dose combinations |
| Calcium-channel blockers | Amlodipine, nifedipine | Effective once-daily therapy |
| Beta blockers | Metoprolol, atenolol | Selected cardiovascular indications |
| Modern fixed-dose combinations | ARB/thiazide, ACE inhibitor/CCB, ARB/CCB | Better prescribing flexibility and commercial support |
Guidelines from the American College of Cardiology and American Heart Association generally prioritize thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers, depending on patient characteristics. Deserpidine is not a routine first-line component of contemporary hypertension treatment. (Whelton et al., 2018)
The combination’s main disadvantage is not price. It is clinical obsolescence relative to drugs with better evidence, more predictable use, and stronger physician familiarity.
What is the FDA regulatory status?
The product is a conventional small-molecule antihypertensive, not a biologic, biosimilar, controlled substance, or advanced therapy. FDA regulatory value is limited by the product’s age and narrow commercial relevance.
Relevant regulatory characteristics include:
- Prescription antihypertensive classification
- Oral fixed-dose tablet
- No biosimilar pathway
- No current innovation exclusivity
- Legacy labeling and safety information
- Limited strategic value from a new drug application unless a sponsor seeks a reformulation or relaunch
A relaunch would require more than acquiring a historical label. The sponsor would need to establish current manufacturing compliance, product availability, labeling strategy, pharmacovigilance, and a commercially credible reason for physicians and payers to use the product.
Which companies are challenging or commercializing the product?
No major current competitor is publicly associated with an active branded investment campaign for deserpidine/methyclothiazide. The market is more likely to consist of legacy-label holders, contract manufacturers, small generic companies, and distributors than large pharmaceutical innovators.
The commercial landscape is fragmented because:
- The active ingredients are old and inexpensive.
- Demand is limited.
- Switching costs are low.
- Prescribers have many alternatives.
- There is no meaningful patent-based market window.
- Marketing investment would be difficult to recover.
No major licensing transaction, acquisition premium, or strategic partnership is publicly recognized as being driven by this specific combination. Any licensing value would likely depend on a broader portfolio transaction involving legacy antihypertensive products rather than the combination alone.
What is the financial trajectory of deserpidine/methyclothiazide?
The financial trajectory is structurally negative or flat at a very low base.
Revenue drivers
| Driver | Effect on financial outlook |
|---|---|
| Unit demand | Declining as prescribing shifts to modern agents |
| Average selling price | Low because of generic competition and limited differentiation |
| Gross margin | Potentially acceptable for a low-cost legacy product, but vulnerable to small-volume manufacturing |
| Marketing expense | Usually limited because market expansion is unlikely |
| Supply economics | Can be unfavorable if batch sizes are small |
| Pricing power | Weak |
| Reimbursement leverage | Limited |
| Licensing value | Low |
| Litigation value | Negligible |
A small supplier may retain the product because it fills a portfolio gap, uses existing manufacturing capacity, or serves a residual patient population. That does not imply attractive growth. The asset can remain commercially available while generating little strategic value.
What generic launch risks exist?
Generic launch risk is low from a patent perspective but moderate from a supply and market-size perspective.
Generic entry scenario
| Scenario | Likely outcome |
|---|---|
| New generic entrant | Rapid price pressure if demand is sufficient |
| Existing supplier exits | Temporary shortage risk because few manufacturers may remain |
| Brand relaunch | Low probability without a differentiated formulation or channel |
| Authorized generic | Limited strategic rationale |
| Reformulation | Commercially difficult unless linked to a new indication or delivery advantage |
| Manufacturing transfer | Manageable but potentially uneconomic at low volumes |
The principal risk is not a sudden patent-enabled generic wave. It is gradual erosion, intermittent supply, and eventual withdrawal if production costs exceed contribution margin.
What geographic coverage does the product have?
Deserpidine/methyclothiazide has limited strategic relevance outside markets where legacy antihypertensive products remain registered and where low-cost treatment access supports continued use.
Geographic commercialization is constrained by:
- Country-specific registration status
- Local availability of active pharmaceutical ingredients
- Pharmacopoeial and quality requirements
- National treatment guidelines
- Reimbursement policies
- Small patient populations
- Lack of multinational promotional support
The United States offers little apparent growth potential. International residual markets may exist, but they are unlikely to create a material global revenue opportunity without evidence of active registrations, supply contracts, or local demand.
Key Takeaways
- Deserpidine/methyclothiazide is a legacy fixed-dose antihypertensive combination with minimal current commercial momentum.
- Its active ingredients and combination technology are long past the period of meaningful patent exclusivity.
- No material current Orange Book patent or regulatory-exclusivity barrier drives market access.
- Paragraph IV litigation and biosimilar risk are not meaningful factors.
- The formulation is a conventional oral tablet with low technical and IP defensibility.
- Modern antihypertensive classes have displaced deserpidine in routine prescribing.
- Product-level revenue is not publicly disclosed, but the market profile indicates low and declining revenue.
- Residual value depends on supply continuity, portfolio economics, and niche distribution rather than innovation or patent protection.
- A generic entrant could access the market without facing a meaningful core patent barrier, although limited demand may reduce launch incentives.
FAQs
Is deserpidine/methyclothiazide still used for high blood pressure?
It may remain available in limited markets or through legacy supply channels, but it is not a routine first-line choice in contemporary hypertension management.
Is Diupres still a patented drug?
No commercially meaningful patent protection is expected to remain for the original deserpidine/methyclothiazide combination.
Can a generic manufacturer launch deserpidine/methyclothiazide?
A manufacturer could pursue the applicable FDA small-molecule approval pathway, subject to current regulatory, manufacturing, and labeling requirements. Patent-based launch restrictions do not appear to be the principal barrier.
Does deserpidine/methyclothiazide have biosimilar competition?
No. Biosimilars apply to biologic products. Deserpidine/methyclothiazide is a conventional small-molecule tablet.
Why did deserpidine/methyclothiazide lose market share?
Physicians shifted toward antihypertensive agents with stronger clinical evidence, better tolerability, broader guideline support, and more flexible fixed-dose combinations.
References
-
National Library of Medicine. (n.d.). DailyMed: Deserpidine and methyclothiazide tablet labeling. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, 45th edition. Center for Drug Evaluation and Research.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
More… ↓
